Verona Pharma Net Worth
Verona Pharma Net Worth Breakdown | VRNA |
Verona Pharma Net Worth Analysis
Verona Pharma's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Verona Pharma's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Verona Pharma's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Verona Pharma's net worth analysis. One common approach is to calculate Verona Pharma's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Verona Pharma's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Verona Pharma's net worth. This approach calculates the present value of Verona Pharma's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Verona Pharma's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Verona Pharma's net worth. This involves comparing Verona Pharma's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Verona Pharma's net worth relative to its peers.
Enterprise Value |
|
To determine if Verona Pharma is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Verona Pharma's net worth research are outlined below:
| Verona Pharma PLC appears to be risky and price may revert if volatility continues | |
| The company reported the previous year's revenue of 458 K. Net Loss for the year was (54.58 M) with profit before overhead, payroll, taxes, and interest of 5.08 M. | |
| Verona Pharma PLC currently holds about 111.51 M in cash with (50.22 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.83. | |
| Verona Pharma PLC has a poor financial position based on the latest SEC disclosures | |
| Over 89.0% of the company outstanding shares are owned by institutional investors | |
| Latest headline from investors.com: Exact Sciences Stock Drops 12 percent Over Four Days. What Is Going On |
Verona Pharma Quarterly Good Will |
|
Verona Pharma uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Verona Pharma PLC. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Verona Pharma's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 5th of March 2024 Upcoming Quarterly Report | View | |
| 14th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 5th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Verona Pharma Target Price Consensus
Verona target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Verona Pharma's target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 8 | Strong Buy |
Most Verona analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Verona stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Verona Pharma PLC, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationVerona Pharma Target Price Projection
Verona Pharma's current and average target prices are 51.89 and 61.00, respectively. The current price of Verona Pharma is the price at which Verona Pharma PLC is currently trading. On the other hand, Verona Pharma's target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Current Price
Verona Pharma Market Quote on 18th of January 2025
Target Price
Analyst Consensus On Verona Pharma Target Price
Know Verona Pharma's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Verona Pharma is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Verona Pharma PLC backward and forwards among themselves. Verona Pharma's institutional investor refers to the entity that pools money to purchase Verona Pharma's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Caligan Partners Lp | 2024-09-30 | 1.4 M | Hood River Capital Management Llc | 2024-09-30 | 1.4 M | T. Rowe Price Associates, Inc. | 2024-09-30 | 1.3 M | Bellevue Group Ag | 2024-09-30 | 1.2 M | Citadel Advisors Llc | 2024-09-30 | 1.2 M | Aisling Capital Management Lp | 2024-09-30 | 1.1 M | Loomis, Sayles & Company Lp | 2024-09-30 | 1.1 M | Hhg Plc | 2024-09-30 | 1 M | Rice Hall James & Associates, Llc | 2024-09-30 | 985.1 K | Perceptive Advisors Llc | 2024-09-30 | 6.3 M | Nea Management Company, Llc | 2024-09-30 | 5.6 M |
Follow Verona Pharma's market capitalization trends
The company currently falls under 'Mid-Cap' category with a current market capitalization of 4.25 B.Market Cap |
|
Project Verona Pharma's profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.16) | (0.17) | |
| Return On Capital Employed | (0.26) | (0.27) | |
| Return On Assets | (0.20) | (0.21) | |
| Return On Equity | (0.25) | (0.26) |
When accessing Verona Pharma's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Verona Pharma's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Verona Pharma's profitability and make more informed investment decisions.
Please note, the presentation of Verona Pharma's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Verona Pharma's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Verona Pharma's management manipulating its earnings.
Evaluate Verona Pharma's management efficiency
Verona Pharma PLC has return on total asset (ROA) of (0.2805) % which means that it has lost $0.2805 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.7803) %, meaning that it created substantial loss on money invested by shareholders. Verona Pharma's management efficiency ratios could be used to measure how well Verona Pharma manages its routine affairs as well as how well it operates its assets and liabilities. As of January 18, 2025, Return On Tangible Assets is expected to decline to -0.17. In addition to that, Return On Capital Employed is expected to decline to -0.27. At present, Verona Pharma's Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Current Assets Total is expected to grow to about 22.2 M, whereas Return On Tangible Assets are forecasted to decline to (0.17).| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 2.83 | 2.97 | |
| Tangible Book Value Per Share | 2.82 | 2.97 | |
| Enterprise Value Over EBITDA | (23.25) | (24.41) | |
| Price Book Value Ratio | 7.27 | 6.91 | |
| Enterprise Value Multiple | (23.25) | (24.41) | |
| Price Fair Value | 7.27 | 6.91 | |
| Enterprise Value | 1.2 B | 1.2 B |
Leadership effectiveness at Verona Pharma PLC is a strong indicator of its financial stability. We analyze various metrics to provide insights into the stock's investment viability.
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Verona Pharma insiders, such as employees or executives, is commonly permitted as long as it does not rely on Verona Pharma's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Verona Pharma insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Verona Pharma Corporate Filings
8K | 7th of January 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 6th of December 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
13A | 14th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
F3 | 28th of August 2024 An amendment to the original Schedule 13D filing | ViewVerify |
Verona Pharma Earnings Estimation Breakdown
The calculation of Verona Pharma's earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Verona Pharma is estimated to be -0.5175 with the future projection ranging from a low of -0.565 to a high of -0.4675. Please be aware that this consensus of annual earnings estimates for Verona Pharma PLC is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
-0.56 Lowest | Expected EPS | -0.47 Highest |
Verona Pharma Earnings Projection Consensus
Suppose the current estimates of Verona Pharma's value are higher than the current market price of the Verona Pharma stock. In this case, investors may conclude that Verona Pharma is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Verona Pharma's stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of December 2024 | Current EPS (TTM) | |
| 8 | 59.46% | -0.56 | -0.5175 | -2.0 |
Verona Pharma Earnings per Share Projection vs Actual
Actual Earning per Share of Verona Pharma refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering Verona Pharma PLC predict the company's earnings will be in the future. The higher the earnings per share of Verona Pharma, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.Verona Pharma Estimated Months Earnings per Share
For an investor who is primarily interested in generating an income out of investing in entities such as Verona Pharma, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of Verona Pharma should always be considered in relation to other companies to make a more educated investment decision.Verona Quarterly Analyst Estimates and Surprise Metrics
Earnings surprises can significantly impact Verona Pharma's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-11-04 | 2024-09-30 | -0.5 | -0.56 | -0.06 | 12 | ||
2024-08-01 | 2024-06-30 | -0.37 | -0.88 | -0.51 | 137 | ||
2024-05-09 | 2024-03-31 | -0.16 | -0.32 | -0.16 | 100 | ||
2024-02-29 | 2023-12-31 | -0.26 | -0.18 | 0.08 | 30 | ||
2023-11-02 | 2023-09-30 | -0.28 | -0.18 | 0.1 | 35 | ||
2023-08-03 | 2023-06-30 | -0.29 | -0.08 | 0.21 | 72 | ||
2023-05-09 | 2023-03-31 | -0.19 | -0.03 | 0.16 | 84 | ||
2023-03-07 | 2022-12-31 | -0.1 | -0.16 | -0.06 | 60 | ||
2022-11-09 | 2022-09-30 | -0.16 | -0.23 | -0.07 | 43 | ||
2022-08-09 | 2022-06-30 | -0.38 | -0.32 | 0.06 | 15 | ||
2022-05-03 | 2022-03-31 | -0.44 | -0.4 | 0.04 | 9 | ||
2022-03-03 | 2021-12-31 | -0.48 | -0.4 | 0.08 | 16 | ||
2021-11-09 | 2021-09-30 | -0.36 | 0.16 | 0.52 | 144 | ||
2021-08-05 | 2021-06-30 | -0.44 | -0.37 | 0.07 | 15 | ||
2021-04-29 | 2021-03-31 | -0.47 | -0.36 | 0.11 | 23 | ||
2021-02-25 | 2020-12-31 | -0.35 | -0.4 | -0.05 | 14 | ||
2020-10-29 | 2020-09-30 | -0.22 | -0.46 | -0.24 | 109 | ||
2020-08-14 | 2020-06-30 | -0.47 | -0.66 | -0.19 | 40 | ||
2020-04-30 | 2020-03-31 | -0.65 | -0.95 | -0.3 | 46 | ||
2020-02-27 | 2019-12-31 | -1.09 | -0.73 | 0.36 | 33 | ||
2019-11-05 | 2019-09-30 | -0.79 | -0.95 | -0.16 | 20 | ||
2019-08-06 | 2019-06-30 | -0.75 | -0.87 | -0.12 | 16 | ||
2019-05-07 | 2019-03-31 | -0.49 | -0.54 | -0.05 | 10 | ||
2019-02-26 | 2018-12-31 | -0.51 | -0.29 | 0.22 | 43 | ||
2018-11-06 | 2018-09-30 | -0.54 | -0.03 | 0.51 | 94 | ||
2018-08-07 | 2018-06-30 | -0.97 | 0.06 | 1.03 | 106 | ||
2018-05-08 | 2018-03-31 | -0.71 | -1.61 | -0.9 | 126 | ||
2018-02-27 | 2017-12-31 | -0.88 | -0.55 | 0.33 | 37 | ||
2017-11-07 | 2017-09-30 | -0.5 | -0.93 | -0.43 | 86 | ||
2017-08-08 | 2017-06-30 | -0.35 | -0.4 | -0.05 | 14 | ||
2017-04-28 | 2017-03-31 | -0.34 | -0.43 | -0.09 | 26 | ||
null | null | null | null | null | 0 |
Verona Pharma Corporate Management
| Caroline Diaz | Senior Affairs | Profile | |
| LCSW BA | G Counsel | Profile | |
| Matthew Casbon | Marketing Sales | Profile | |
| Peter Spargo | Senior Controls | Profile | |
| Kathleen MD | Chief Officer | Profile | |
| B ASIA | General Counsel | Profile |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Verona Pharma PLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Verona Pharma. If investors know Verona will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Verona Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Verona Pharma PLC is measured differently than its book value, which is the value of Verona that is recorded on the company's balance sheet. Investors also form their own opinion of Verona Pharma's value that differs from its market value or its book value, called intrinsic value, which is Verona Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Verona Pharma's market value can be influenced by many factors that don't directly affect Verona Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Verona Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Verona Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Verona Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.